Pharma & Bio
Technology
SkyLabs Hits Upper Price Limit on U.S. Interest; Orum Therapeutics Extends Its Decline [K-Bio Pulse]
SkyLabs Hits Upper Price Limit on U.S. Attention; Orum Therapeutics Extends SlideSouth Korea’s pharmaceutical and biotech sector saw notable movements on September 21, led by SkyLabs, which hit the up…
Technology
SkyLabs Rises on U.S. Attention… Orum Therapeutics, Inc. Falls for the Second Consecutive Day [Bio Spotlight]
On the 21st, in the pharmaceutical and biotech sector, #SkyLabs stood out the most, hitting the daily price limit after a nine-trading-day downtrend. SkyLabs is a digital healthcare company that manuf…
Technology
National Health Insurance to Cover CGM for Type 2 Diabetes… Can i-SENS, Inc. Break Through Low Market Penetration?
The government has expanded health insurance coverage for continuous glucose monitors (CGMs) to include patients with severe type 2 diabetes, marking a turning point that is expected to boost the low …
Lifestyle
LAMEDITECH Co., Ltd. Enters the Skin Booster Market… Overcoming the Limitations of a Latecomer Through a Platform Strategy
LAMEDITECH Co., Ltd.(462510), a company specializing in laser beauty and medical devices, is entering the extracellular matrix (ECM) skin booster business, which has rapidly emerged as a new paradigm …
Technology
Orum Plunges on Clinical Trial Halt; ENCell and VUNO Jump [K-Bio Pulse]
South Korean biotech stocks saw sharp divergence on September 18, as Orum Therapeutics, Inc. plunged to the daily lower limit following another clinical setback, while ENCell Co., Ltd. and VUNO Inc. p…
Technology
No Respite for K-Bio… Shares Plunge on ‘Clinical Trial Suspension Shock’ [Bio Insight]
On the 18th, the biotech sector was rocked by the shock of #Orum Therapeutics, Inc.’s decision to halt clinical development. Amid this turmoil, some stocks—including #ENCell Co., Ltd. and VUNO, Inc.(3…
Lifestyle
Cholera Vaccine ‘Shortage’ Leads to Mass Vaccination Campaign… EuBiologics Co., Ltd. Sees ‘Boom in Orders’
EuBiologics Co., Ltd.(206650)is emerging as a direct beneficiary of growing global demand for cholera vaccines. Since 97.3% of the company’s revenue comes from cholera vaccines, changes in global dema…
Technology
ORM-6151 Stalled Due to BMS’s Strategic Realignment… Upcoming New Drug Following Orum AML Faces Test of Its Differentiation
Bristol-Myers Squibb (BMS) has halted development of “ORM-6151” (BMS project name BMS-986497), a treatment for acute myeloid leukemia (AML), which it acquired from #Orum Therapeutics, Inc. for an upfr…
Technology
'Tactile Display' Dot Expands Collaboration with Google Gemini... Targeting the Visual Rehabilitation Market
Dot, a social venture that commercialized the world’s first tactile display, is breaking free from the label of “manufacturer of assistive devices for the visually impaired.” The company is expanding …
Technology
[K-Bio’s Expansion into Japan] (2) Same Japan, Different Formula for Success… Celltrion’s Anticancer Drugs Also Rank “No. 1”
Celltrion(068270), which has reclaimed the top spot in Japan’s infliximab market for the first time in about 11 years, has created yet another formula for success in the anti-cancer biosimilar market.…